The Common Pathological Factors Between Polycystic Ovary Syndrome and COVID-19 Infection: A Review

被引:3
|
作者
Alahmadi, Ahlam Abdulaziz [1 ]
机构
[1] King Abdulaziz Univ, Dept Biol Sci, Coll Sci, Jeddah, Saudi Arabia
来源
关键词
POLYCYSTIC OVARY SYNDROME; COVID-19; ANDROGEN; MICROBIOME; INSULIN RESISTANCE; VITAMIN-D SUPPLEMENTATION; FATTY LIVER-DISEASE; INSULIN-RESISTANCE; OXIDATIVE STRESS; WOMEN; POLYMORPHISMS; METAANALYSIS; SYSTEM;
D O I
10.21786/bbrc/13.4/12
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Polycystic ovary syndrome (PCOS) is a widespread hormone condition that engaged in infertility and metabolic disorders, like diabetes and cardiovascular diseases. The prevalence of PCOS among women of reproductive age ranged from 6% to 10%. There are many pathophysiologic factors associated with PCOS development, including increased blood insulin level, which stimulates the overproduction of androgens. The second important factor is the low-grade inflammations that accompany PCOS condition. In March 2020, the World Health Organization (WHO) has been announced the widespread of coronavirus-2 (SARS-CoV-2) disease (COVID-19) as a pandemic. The researchers documented the presence of certain diseases as risk factors for increased COVID-19 infection and severity including diabetes, hypertension, and obesity. This study aims to review PCOS's comorbid conditions that can predispose to increased risk of acquiring COVID-19 infection or magnifying its complications or even causing death. Studies have indicated that women with PCOS have many factors and pathologies that greatly increase the incidence of complications of COVID-19. These factors include excessive androgen production, change in microbiome formation, obesity, insulin resistance, vitamin D deficiency, and NAFLD. These factors cause decreased immunity, increased inflammatory reactions, and increased expression of the ACE2 (the gate that enables the virus to penetrate the cells). Therefore, it is necessary to inform PCOS women in order to increase precautionary measures. These women with complicated health conditions should receive high-level health care.
引用
收藏
页码:1708 / 1716
页数:9
相关论文
共 50 条
  • [31] The Impact of COVID-19 Lockdown on Weight Loss Program in Infertile Polycystic Ovary Syndrome Women with Obesity
    Sustarsic, Ana
    Bokal, Eda Vrtacnik
    Papler, Tanja Burnik
    OBESITY FACTS, 2021, 14 (06) : 650 - 657
  • [32] Does vitamin D supplementation for COVID-19 increase the chances of fertility in women with polycystic ovary syndrome?
    Heidarzadeh, Hamid
    Bahrami-Vazir, Ellahe
    Mohammadi, Azam
    Mohammadnejad, Sara
    ANAESTHESIA PAIN & INTENSIVE CARE, 2022, 26 (04) : 574 - 575
  • [33] Is there a causal nexus between COVID-19 infection, COVID-19 vaccination, and Guillain-Barré syndrome?
    Xiaoxiao Zheng
    Yong Fang
    Yanna Song
    Shan Liu
    Kangding Liu
    Jie Zhu
    Xiujuan Wu
    European Journal of Medical Research, 28
  • [34] Is there a causal nexus between COVID-19 infection, COVID-19 vaccination, and Guillain-Barre syndrome?
    Zheng, Xiaoxiao
    Fang, Yong
    Song, Yanna
    Liu, Shan
    Liu, Kangding
    Zhu, Jie
    Wu, Xiujuan
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2023, 28 (01)
  • [35] Polycystic Ovary Syndrome: Common Questions and Answers
    Williams, Tracy
    Moore, Justin B.
    Regehr, Jared
    AMERICAN FAMILY PHYSICIAN, 2023, 107 (03) : 264 - 272
  • [36] The Interrelationship between HIV Infection and COVID-19: A Review of the Literature
    Wang, Yiyu
    Lai, Yu
    CURRENT HIV RESEARCH, 2024, 22 (01) : 6 - 15
  • [37] Can the treatment of polycystic ovary syndrome with spironolactone prevent severe COVID infection?
    Armanini, Decio
    Sabbadin, Chiara
    De Marco, Luigi
    Bordin, Luciana
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2022, 186 (05) : L11 - L13
  • [38] The causal association between polycystic ovary syndrome and susceptibility and severity of COVID-19: a bidirectional Mendelian randomization study using genetic data
    Si, Yu
    Fei, Yuye
    Ma, Hua
    Xu, Yating
    Ning, Li
    Li, Xiu
    Ren, Qingling
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [39] Phytotherapy of polycystic ovary syndrome: A review
    Azin, Farahnaz
    Khazali, Homayoun
    INTERNATIONAL JOURNAL OF REPRODUCTIVE BIOMEDICINE, 2022, 20 (01) : 13 - 20
  • [40] A Review of Polycystic Ovary Syndrome Treatment
    Marshall, Leisa L.
    US PHARMACIST, 2024, 49 (09)